Snakebite envenoming is a major cause of death and morbidity in tropical parts of the world. Current therapies are based on animal-derived antisera that are associated with a high degree of immunogenicity, high cost, and batch-to-batch variation. Here, we report the results of our ongoing efforts of developing the world’s first fully recombinant antivenom based on human IgGs targeting the key toxins from the notorious black mamba (Dendroaspis polylepis).
|Number of pages||1|
|Publication status||Published - 2016|
|Event||PEGS Europe: Protein & Antibody Engineering Summit 2016 - Lisbon, Portugal|
Duration: 31 Oct 2016 → 4 Nov 2016
|Conference||PEGS Europe: Protein & Antibody Engineering Summit 2016|
|Period||31/10/2016 → 04/11/2016|